Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics

Roche has secured its third antibody-drug conjugate pact of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics.

The agreement will also see U.K.-based Oxford in line for milestone payments that could exceed $1 billion, along with a slice of the royalties from potential sales.